{"id":"W4416405197","doi":"10.1016/j.euo.2025.09.010","title":"Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Hospital; Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Abiraterone; Olaparib; Placebo; Prostate cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001249853,0.0004030144,0.0009300067,0.0003132395,0.0002662306,0.0000485563,0.0002590829,0.00008137999,0.00005558283],"category_scores_gemma":[0.0002080279,0.0002322174,0.00007690226,0.0004585827,0.0004148957,0.0001048661,0.0001011969,0.0005160421,0.00001757495],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007317801,"about_ca_system_score_gemma":0.001600037,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003608174,"about_ca_topic_score_gemma":0.002207151,"domain_scores_codex":[0.9957726,0.001577936,0.0008268081,0.0007611939,0.0003162709,0.0007451756],"domain_scores_gemma":[0.9981194,0.000561949,0.000333155,0.0005571054,0.0003028551,0.0001255213],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7724907,0.01344068,0.05764563,0.000569757,0.009204771,0.01913754,0.0591634,0.001764492,0.009494511,0.0001956657,0.01513432,0.04175847],"study_design_scores_gemma":[0.5932741,0.1155127,0.2234197,0.0001710729,0.004381264,0.0001746264,0.02040491,0.002244597,0.0008897143,0.00007364006,0.03856838,0.0008853056],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9729337,0.0005607548,0.00005735044,0.008722485,0.0003430406,0.009707599,0.00006692357,0.00007145604,0.00753666],"genre_scores_gemma":[0.9910542,0.0000864748,0.0002017305,0.001077315,0.00005226809,0.002395998,0.0001587743,0.00006074513,0.004912542],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1792166,"threshold_uncertainty_score":0.9469551,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06114573341904889,"score_gpt":0.3886800800726639,"score_spread":0.327534346653615,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}